权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Institutional Clinical and Translational Science Award

机构临床和转化科学奖

基本信息

批准号：
10348879
负责人：
GARRET A FITZGERALD
金额：
$ 1016.45万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10348879
关键词：
Academia Address Adherence Adult Antihypertensive Agents Area Biological Models Cell model Childhood Circadian Dysregulation Clinical Clinical Research Clinical Sciences Clinical and Translational Science Awards Communities Complex Development Disadvantaged Discipline Disease Dose Drug Exposure Educational process of instructing Faculty First Independent Research Support and Transition Awards Fostering Fruit Functional disorder Funding Genomic medicine Goals Growth Health system Home Human Incentives Industry Institutes Institution Intensive Care Intervention Trial Leadership Life Lipids London Measures Messenger RNA Mission Modeling Pediatric Hospitals Pennsylvania Pharmaceutical Preparations Pharmacologic Substance Phenotype Philadelphia Physiological Physiology Pilot Projects Price Private Sector Randomized Research Research Personnel Resources Rural Community Schools Science Series Sickle Cell Anemia Testing The Wistar Institute Therapeutic Time Translating Translational Research United States National Institutes of Health Universities Urban Community Validation Vision cardiovascular risk factor clinical implementation clinical investigation college drug action implementation barriers implementation science improved improved outcome medical schools novel novel therapeutics phenomics pre-clinical precision medicine programs recruit response success translational medicine uptake

项目摘要

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade and a half the objectives of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 136 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

联系PD/PI：FITZGERALD、GARRET A 整体摘要/总结转化医学和治疗研究所是CTSA的学术之家，宾夕法尼亚州在过去的15年里，ITMAT的目标一直是而且仍然是：增加有能力在有证据证明细胞和模型系统中的概念，以及（ii）阐明人体生理学的机制，疾病或药物的作用，通过强烈的表型在少数人。两我们的CTSA的优先事项是促进转化治疗领域，并弥合从儿科到成人，跨越了临床和转化科学的整个范围。这本节介绍了这些优先事项如何影响CTSA中心的发展，并概述了我们对未来融资期的计划。项目摘要/摘要第136页联系PD/PI：FITZGERALD、GARRET A 整体叙事转化医学和治疗研究所是CTSA的学术之家，宾夕法尼亚州在过去十年中，ITMAT的具体目标一直是而且仍然是：㈠增加许多研究人员能够在细胞概念验证之间继续进行研究和模型系统，以及（ii）阐明人类生理学、疾病或药物作用通过在少数人中的强烈表型。